# The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report

## TL;DR

A 64-year-old woman with EGFR-mutated lung cancer did not respond well to osimertinib for bone metastasis, highlighting the need for better targeted treatments.

## Contribution

This case report highlights osimertinib's limited effectiveness in treating bone metastasis in EGFR-mutated lung cancer.

## Key findings

- Osimertinib showed initial response but failed to significantly affect bone metastasis.
- The patient's condition eventually required palliative care despite treatment.
- The case underscores the need for alternative therapies for bone metastasis in lung cancer.

## Abstract

This case report examines the effectiveness of osimertinib in a 64-year-old non-smoking female diagnosed with stage IV lung adenocarcinoma and an epidermal growth factor receptor (EGFR) exon 19 mutation, focusing on the treatment’s impact on bone metastasis. Despite initial responsiveness to osimertinib, the patient's bone lesions remained largely unresponsive, prompting a comprehensive exploration of alternative treatments and clinical trials. This report highlights the patient's clinical journey, from diagnosis through various treatment phases, culminating in palliative care, and underscores the need for further research into targeted treatments for bone metastasis in lung cancer.